

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

# Clinical Microbiology and Infection



journal homepage: www.clinicalmicrobiologyandinfection.com

**Original Article** 

# Characteristics of human metapneumovirus infection in adults hospitalized for community-acquired influenza-like illness in France, 2012–2018: a retrospective observational study

P. Loubet <sup>1, 2, \*, ‡</sup>, P. Mathieu <sup>3, ‡</sup>, N. Lenzi <sup>2</sup>, F. Galtier <sup>2, 4</sup>, F. Lainé <sup>2, 5</sup>, Z. Lesieur <sup>2</sup>, P. Vanhems <sup>2, 6</sup>, X. Duval <sup>2, 7</sup>, D. Postil <sup>8</sup>, S. Amour <sup>6</sup>, S. Rogez <sup>9</sup>, G. Lagathu <sup>10</sup>, A.-S. L'Honneur <sup>11</sup>, V. Foulongne <sup>12</sup>, N. Houhou <sup>13</sup>, B. Lina <sup>14</sup>, F. Carrat <sup>15</sup>, O. Launay <sup>2, 3</sup>, on behalf of the Fluvac study group

1) VBMI, INSERM U1047, Department of Infectious and Tropical Disease, CHU Nîmes, Univ Montpellier, Nîmes, France

<sup>2)</sup> Inserm, F-CRIN, Réseau Innovative Clinical Research in Vaccinology (I-REIVAC), Paris, France

<sup>3)</sup> Université Paris Descartes, Sorbonne Paris Cité, Inserm, CIC Cochin Pasteur, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France

<sup>4)</sup> CIC1411, CHU Montpellier, Hôpital Saint Eloi, Montpellier, F-34295, France

<sup>5)</sup> Centre d'Investigations Cliniques, INSERM UMR CIC 1414, Hôpital Pontchaillou, Rennes, France

<sup>6)</sup> Service d'Hygiene, Epidemiologie et Prevention, Hospices Civils de Lyon, F-69437 Lyon, France

<sup>7)</sup> CIC1125, Hôpital Bichat Claude Bernard, Paris, France

<sup>8)</sup> CHU Dupuytren, CIC 1435, Limoge Cedex, France

<sup>9)</sup> CHU Dupuytren, Service Bactériologie, Virologie, Hygiène, Limoges Cedex, France

<sup>10)</sup> Universite Rennes-I, Virologie, Hôpital Pontchaillou, Rennes, France

<sup>11)</sup> AHU, Service de Virologie, Hôpital Cochin, Paris, France

<sup>12)</sup> Service de Virologie, CHU Montpellier, Hôpital Saint Eloi, Montpellier, F-34295, France

<sup>13)</sup> Laboratoire de Virologie, Hôpital Bichat Claude Bernard, Paris, France

<sup>14)</sup> Hospices Civils de Lyon, Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Centre National de Référence des virus Respiratoires France Sud, Hôpital de la Croix-Rousse, 69317 Lyon Cedex 04, France

<sup>15)</sup> Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique IPLESP, AP-HP, Hôpital Saint Antoine, F75013 Paris, France

# ARTICLE INFO

Article history: Received 5 January 2020 Received in revised form 27 March 2020 Accepted 4 April 2020 Available online 10 April 2020

Editor: A. Huttner

Keywords: Adults Human metapneumovirus Influenza Influenza-like-illness Respiratory syncytial virus

# ABSTRACT

*Objectives:* To describe the prevalence, clinical features and complications of human metapneumovirus (hMPV) infections in a population of adults hospitalized with influenza-like illness (ILI).

*Methods:* This was a retrospective, observational, multicenter cohort study using prospectively collected data from adult patients hospitalized during influenza virus circulation, for at least 24 h, for community-acquired ILI (with symptom onset <7 days). Data were collected from five French teaching hospitals over six consecutive winters (2012–2018). Respiratory viruses were identified by multiplex reverse transcription polymerase chain reaction (RT-PCR) on nasopharyngeal specimens. hMPV + patients were compared with hMPV– patients, influenza+ and respiratory syncytial virus (RSV)+ patients using multivariate logistic regressions. Primary outcome was the prevalence of hMPV in patients hospitalized for ILI.

*Results*: Among the 3148 patients included (1449 (46%) women, 1988 (63%) aged 65 and over; 2508 (80%) with chronic disease), at least one respiratory virus was detected in 1604 (51%, 95% confidence interval (CI) 49–53), including 100 cases of hMPV (100/3148, 3% 95% CI 3–4), of which 10 (10%) were viral co-infection. In the hMPV + patients, mean length of stay was 7 days, 62% (56/90) developed a complication, 21% (14/68) were admitted to intensive care unit and 4% (4/90) died during hospitalization. In comparison with influenza + patients, hMPV + patients were more frequently >65 years old (adjusted odds ratio (aOR) = 3.3, 95% CI 1.9–6.3) and presented more acute heart failure during hospitalization (aOR = 1.8, 95% CI 1.0–2.9). Compared with RSV + patients, hMPV + patients had less cancer (aOR = 0.4, 95% CI 0.2–0.9) and were less likely to smoke (aOR = 0.5, 95% CI 0.2–0.9) but had similar outcomes, especially high rates of respiratory and cardiovascular complications.

https://doi.org/10.1016/j.cmi.2020.04.005

1198-743X/© 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

<sup>\*</sup> Corresponding author. P. Loubet, Service des Maladies infectieuses et tropicales, CHU Nîmes, Nîmes, France.

E-mail address: paul.loubet@chu-nimes.fr (P. Loubet).

<sup>&</sup>lt;sup>‡</sup> These authors contributed equally to this work.

*Conclusions:* Adult hMPV infections mainly affect the elderly and patients with chronic conditions and are responsible for frequent cardiac and pulmonary complications similar to those of RSV infections. Atrisk populations would benefit from the development of antivirals and vaccines targeting hMPV. **P. Loubet, Clin Microbiol Infect 2021;27:127.e1–127.e6** 

© 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

# Introduction

During winter, community-acquired influenza-like illness (ILI), mostly caused by respiratory viruses, is very common. The most frequent viruses seen in primary care are influenza viruses A/B, rhinovirus, coronavirus, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) [1,2]. In the hospital setting, adults with ILI are commonly tested only for influenza, resulting in limited data concerning other respiratory viruses. The use of multiplex reverse transcription polymerase chain reaction (RT-PCR) allows identification of multiple viruses simultaneously but remains a second-line test in non-immunocompromised patients in emergency departments because of its cost and the limited therapeutic options [3].

Human MPV, discovered in 2001, is phylogenetically similar to RSV and has been frequently found to be associated with respiratory tract illnesses [1,4,5]. Its circulation occurs with a seasonal distribution from January to March in the Northern hemisphere, often overlapping or following RSV infection season [6,7]. Human MPV is a major paediatric respiratory pathogen [8] but can affect all age groups, especially persons with chronic conditions [9], leading to diverse clinical presentation from upper respiratory tract symptoms to severe pneumonia [10,11].

While hMPV is known to contribute substantially to the burden of wintertime respiratory illnesses in adults [12], data on its frequency and comparison with other respiratory viruses in large adult populations are scarce.

We aimed to (a) describe the clinical characteristics and outcome of hMPV infection and (b) compare hMPV with influenza and RSV infections in adults hospitalized for community-acquired ILI in France in winter between 2012 and 2018.

## Methods

# Study design

We performed a post hoc, retrospective analysis of the FLUVAC study. FLUVAC is a French prospective case-test negative design study evaluating influenza vaccine effectiveness on influenzaassociated hospitalization conducted in five (2012/13, 2015/16 to 2017/18) or six (2013/14 to 2014/15) teaching hospitals. All adults hospitalized for at least 24 h for ILI during the influenza circulation period, with symptom onset <7 days before screening, were included in FLUVAC. ILI was defined according to the European Centre for Disease Prevention and Control (ECDC) definition [13] as a combination of the following: (a) at least one of the following systemic symptoms – fever or feverishness, headache, myalgia or malaise; and (b) at least one of the following respiratory symptoms - cough, sore throat or dyspnea. Patients with contra-indication for influenza immunization, those who had previously tested positive for influenza virus in the same season and those without a French social security affiliation were excluded. Each participant was interviewed, and nasopharyngeal samples were obtained at enrolment to screen for influenza and other respiratory viruses.

In the present study, we included all the patients from the first six FLUVAC seasons (2012/13, 2013/14, 2014/15, 2015/16, 2016/17,

2017/18) for whom virologic results on respiratory viruses were available (Fig. 1).

#### Outcomes

The primary outcome was the prevalence of confirmed hMPV infection in patients hospitalized with ILI. Secondary outcomes were the demographic characteristics, chronic underlying diseases and treatments, clinical presentation of the ILI episode and




Fig. 1. Flowchart. hMPV, human metapneumovirus; ILI, influenza-like illness; RSV, respiratory syncytial virus.

complications, intensive care unit admission or death in patients with hMPV infections.

# Microbiological data

Respiratory viruses were identified using multiplex RT-PCR performed on nasopharyngeal swabs. Clinical bronchoalveolar lavage fluid samples and tracheal aspirates were also tested. Samples were first tested in the virology laboratory of each participating hospital using real-time (RT) influenza A and B PCR after manual nucleic acid extraction. All samples were then sent to the French National Influenza Reference Centre (CNR-Lyon) for influenza confirmation and screening for other respiratory viruses (adenoviruses, bocaviruses, hMPV, picornavirus, RSV, coronaviruses, parainfluenza viruses (since 2013)) by RT-PCR using the Respiratory Multiwell System r-gene® on an ABI 7300 analyser between 2012/13 and 2014/15. From 2015/16, all the virology laboratories of the five sites used the same Eurobio kit and only B lineage was provided by the CNR-Lyon.

# Statistical analysis

Quantitative variables were expressed as mean and standard deviation (SD) or median and interquartile range (IQR), and qualitative variables as number and percentage. Qualitative variables were compared using the  $\chi^2$  and Fisher's exact tests, as appropriate. Quantitative variables were compared by Wilcoxon rank sum test. Missing data for each variable were excluded from the denominator.

Patients with multiple viral infections were excluded from the analyses. Univariate analysis was used to asses risk factors for the detection of hMPV infection, influenza infection, RSV infection and acute heart failure. We performed two multivariate analyses using a backward stepwise logistic regression model using hMPV test result (positive/negative) and acute heart failure (yes/no) as the dependent variable in the first and second model, respectively. Covariates with a p-value <0.2 in univariate analysis were tested in the multivariate model. Results from regression models are expressed as crude odds ratios (OR) and adjusted ORs (aOR) with 95% CI. A p-value of <0.05 was considered statistically significant. Analyses were performed using R software (Version 1.1.463).

# Ethics

The FLUVAC study (clinicaltrials.gov NCT02027233) followed Good Epidemiological and Clinical Practices in Clinical Research, and the Declaration of Helsinki, and was approved by the regional ethics committees. All the study participants gave their informed consent for respiratory virus testing.

#### Results

# Comparison of hMPV+ and hMPV- patients

Of the 3148 patients included in the FLUVAC study, 1604 (51%, 95% CI 49–53) tested positive for at least one respiratory virus. Most had influenza (1123/1604, 70%, 95% CI 68–72), while 167 had picornavirus (10%, 95% CI 9–12), 145 had RSV (9%, 95% CI 8–10), 100 had hMPV (6%, 95% CI 5–7), 38 had adenovirus (2%, 95% CI 2–3) and 23 had bocavirus (1%, 95% CI 1–2) (Fig. 1, Supplementary Table S1). Ten of the 100 hMPV infections (10%) were co-infection cases with at least one other virus: three with influenza A virus, one with coronavirus, one with both influenza A virus and coronavirus, two with picornavirus, one with parainfluenza virus, one with adenovirus and one with RSV.

Overall, 3% (95% CI 3–4) of people with ILI symptoms (90/3148) tested positive for hMPV. Peak hMPV detection occurred between

mid-January and mid-February (Supplementary Figs S1, S2). While patients with hMPV infections were generally older than those without (median age 78 years (IQR 70–86) vs 71 years (IQR 57–83), p < 0.001), other demographic characteristics were similar. Most patients with hMPV presented at least one chronic condition (81%, 73/90), mostly cardiac (50%, 45/90) and respiratory (44%, 40/90) chronic diseases, 17% under immunosuppressive treatment (15/90), 14% active smokers (12/87) and 41% (37/90) hospitalized in the 12 months preceding the study (Table 1).

The median time from symptom onset to admission was similar between hMPV+ and hMPV- patients (2 days (IQR 1–3)) as well as the main symptoms at inclusion except for weakness/malaise that was less frequent in hMPV + patients (13/90 (14%) vs 27%, p < 0.007).

There was no difference between hMPV+ and hMPV- groups in terms of median length of stay, number of complications during hospitalization, intensive care unit (ICU) admission and death. However, hMPV + patients were more likely to have an acute heart failure during hospitalization (25% (22/89) vs 14% (377/2722), p < 0.004).

There was no difference in sociodemographic characteristics, clinical presentation or outcomes between hMPV and viral coinfection and patients with hMPV infections alone.

In the multivariate analysis, when comparing hMPV + patients to all hMPV- patients, age >65 years (aOR 95% CI 3.3 (1.9; 6.1), p < 0.001) was significantly associated with hMPV detection. In contrast, the sudden onset of symptoms, defined as the occurrence of malaise/weakness, was associated with the absence of hMPV infection (aOR 95% CI 0.4 (0.2; 0.8), p = 0.008) (Table 1).

After adjustment for chronic heart disease, age, gender, smoking status and influenza vaccination, hMPV infection was significantly associated with occurrence of acute heart failure during hospitalization (aOR 95% CI 1.8 (1.1; 3.0), p = 0.02).

# Comparison of hMPV and influenza + patients

In univariate analysis, in comparison with influenza + patients, hMPV + patients were older (median age 78 IQR (70–86) vs 69 IQR (54–82) years, respectively, p < 0.001), more vaccinated against influenza (58% vs 39% respectively, p < 0.001), presented more dyspnea at inclusion (p = 0.05) but less weakness (p = 0.01), headache (p = 0.01) and sore throat (p = 0.008). They were more likely to present acute heart failure during the hospital stay (p = 0.002). Other outcomes were not significantly different (Table 2).

In the final model from multivariate analysis, in comparison with influenza + patients, hMPV + patients were more frequently >65 years old (aOR 3.3 (1.9–6.3), P < 0.001).

# Comparison of hMPV+ and RSV + patients

In univariate analysis, hMPV + patients had less chronic disease (p = 0.04), including chronic renal failure (p = 0.04) and cancer (p=0.05) and were less likely to smoke (p=0.05) than RSV + patients. In the final multivariate model, in comparison with RSV + patients, hMPV + patients had less cancer (aOR = 0.4 (0.2–0.9), p = 0.02) and were less likely to smoke (aOR = 0.5 (0.2–0.9), P=0.04). Clinical presentation and outcomes were similar between the two groups (Table 2).

# Discussion

In our post hoc analysis of 3148 hospitalized adult patients with community-acquired ILI, hMPV was found in 3% of the samples. These patients were older, had chronic conditions, frequent respiratory and cardiac chronic diseases, and frequently presented

#### Table 1

Clinical characteristics and outcomes of hospitalized patients infected with human Metapneumovirus compared with patients without human metapneumovirus, 2012–2018

	hMPV-( $n = 3048$ )	hMPV+ ( <i>n</i> = 90)	Univariate analysis	Multivariate analysis					
				Crude OR		р	Adjusted OR		р
Baseline characteristics									
Gender									
Women, <i>n</i> (%)	1390/3048 (46%)	50/90 (56%)	0.06	1.5	(1.0; 2.3)	0.08			
Men, <i>n</i> (%)	1658/3048 (54%)	40/90 (44%)							
Age									
Median age, years (IQR)	71 (56-82)	78 (70-86)	< 0.001						
Age >65 years, $n$ (%)	1904/3048 (62%)	76/90 (84%)	< 0.001	2.9	(1.6; 5.7)	0.001	3.3	(1.9; 6.1)	< 0.001
Median BMI, kg/m <sup>2</sup> (IQR)	24.8 (21.5-28.5)	25.4 (21.1-29.3)							
Smoking status									
Smoker, n (%)	641/2938	12/87 (14%)	0.07	0.9	(0.5; 1.7)	0.84			
Ex-smoker, n (%)	973/2938	28/87 (32%)	0.93						
Non-smoker, n (%)	1324/2938	47/87 (54%)	0.12						
Chronic diseases (at least one), n (%)	2428/3048 (80%)	73/90 (81%)	0.74						
Chronic respiratory disease, n (%)	1361/3048 (45%)	40/90 (44%)	0.96						
Chronic heart disease, n (%)	1267/3048 (42%)	45/90 (50%)	0.12	1.1	(0.7; 1.8)	0.57			
Diabetes, n (%)	714/3048 (23%)	18/90 (20%)	0.52						
Chronic renal failure, n (%)	468/3048 (15%)	9/90 (10%)	0.17	0.5	(0.2; 1.0)	0.08			
Cancer, n (%)	515/3048 (17%)	13/90 (14%)	0.45						
Cirrhosis, n (%)	109/3035 (4%)	4/90 (4%)	0.55						
Immunosuppressive treatment, $n$ (%)	514/3043 (17%)	15/90 (17%)	0.85						
Pregnancy, $n$ (% of women of childbearing age)	28/339 (8%)	0	1						
Influenza vaccination, <i>n</i> (%)	1418/3011 (47%)	52/90 (58%)	0.03	1.1	(0.7; 1.7)	0.69			
Hospitalization in the previous 12 months, $n$ (%)	1405/3031 (46%)	37/90 (41%)	0.33						
Presence of child/children <5 years in the household, $n$ (%)	182/3025 (6%)	5/90 (6%)	0.80						
Clinical presentation		-,()							
Median time from symptom onset	2 (1-3)	2 (1-3)	0.7						
to hospitalization, days (IQR)	2(1 3)	2(1 3)	017						
Symptoms									
Fever or feverishness, <i>n</i> (%)	2562/3045 (84%)	79/90 (88%)	0.40						
Cough, $n$ (%)	2360/3045 (78%)	75/90 (83%)	0.18	1.5	(0.9; 2.7)	0.18			
Dyspnea, $n$ (%)	1739/2199 (79%)	76/90 (84%)	0.54	110	(010, 217)	0110			
Weakness/malaise, n (%)	821/3041 (27%)	13/90 (14%)	0.007	0.5	(0.2; 0.8)	0.01	0.4	(0.2; 0.8)	0.008
Headache, $n$ (%)	755/3032 (25%)	16/90 (18%)	0.08	0.8	(0.2; 0.0) (0.4; 1.4)	0.44	0.1	(0.2, 0.0)	0.000
Myalgia, n (%)	734/3029 (24%)	19/90 (21%)	0.45	0.0	(0.1, 1.1)	0.11			
Sore throat, n (%)	439/3024 (15%)	8/90 (9%)	0.10	0.8	(0.3; 1.5)	0.48			
Outcome	135/3021(13/0)	0/50 (5%)	0.10	0.0	(0.5, 1.5)	0.10			
At least one complication during the hospital stay, $n$ (%)	1648/3148 (52%)	56/90 (62%)	0.13						
Pneumonia*, $n$ (%)	918/3124 (29%)	32/89 (36%)	0.13						
Respiratory failure, n (%)	873/3124 (28%)	32/89 (36%)	0.27						
Acute heart failure, $n$ (%)	420/3122 (13%)	22/89 (25%)	0.004						
Acute respiratory distress syndrome, $n$ (%)	257/3123 (8%)	8/89 (9%)	0.004						
Median length of stay, days (IQR)	5 (3–9)	8/89 (9%) 7 (4–13)	0.85						
ICU admission after hospitalization in acute care, <i>n</i> (%)	543/2283 (24%)	15/90 (17%)	0.50						
Death, <i>n</i> (%)	137/3131 (4%)	4/90 (4%)	1						

BMI, body mass index; hMPV, human metapneumovirus; ICU, intensive care unit; IQR, interquartile range; OR, odds ratio.

complications. This prevalence is consistent with several studies that found hMPV in 3–6% of adult patients with lower respiratory tract infection in primary care [1,14–16] and in 6% of patients hospitalized for acute respiratory infection (ARI) [17]. This frequency may vary according to the inclusion criteria, especially temperature cut-off, as hMPV infection frequently causes non-febrile illness [5].

Our hospitalized hMPV + adults were mostly older and/or highrisk patients as previously described in the literature [5,10,18–20]. Complications were frequent (62%), as well as ICU admission (17%) and death (4%). These rates were similar to those of the 91 hospitalized patients with hMPV from the Walsh et al. study in 2008 in the USA [10], but lower than those of the 128 critically ill adults with hMPV infection (31% required ICU admission and 8% died) from the Hasvold et al. study in 2016 [20].

The majority of hMPV + patients presented several respiratory signs (cough, dyspnea), whereas sudden onset of symptoms was associated with the absence of hMPV infection. There were differences in clinical presentation between hMPV + patients and influenza + patients (less frequent constitutional symptoms (headache, weakness, myalgia) but more dyspnea) but not between

hMPV + patients and RSV + patients. These points emphasize the difficulty in distinguishing between respiratory viruses based on clinical signs alone and question the relevance of the current ILI definition to detect hMPV infection.

Interestingly, we also found that hMPV + patients were older and presented more chronic cardiac conditions and acute heart failure during the hospitalization than influenza + patients. Although, influenza [21] and RSV [22] are known to worsen heart failure, no study has specifically assessed hMPV [21,22]. In our study, hMPV infection was independently associated with the occurrence of acute heart failure.

Several limitations should be acknowledged. First, we enrolled patients during influenza virus circulation but hMPV circulation does not always match that of influenza. Second, we had no data to support causality between the detection of hMPV in nasopharyngeal samples and the ILI hospital admission. Other pathogens such as respiratory bacteria may have been involved and hMPV may have been a concomitant infectious agent with no role in the symptoms reported. The absence of data on bacteriological results prevents us from addressing this issue. Finally, although asymptomatic carriage of hMPV appears to be uncommon [23], we had no

#### Table 2

Sociodemographic, clinical characteristics and outcome of hospitalized patients infected with human metapneumovirus, compared with respiratory syncytial virus and influenza virus infected patients, 2012-2018

	hMPV+(n = 90)	Influenza $+$ ( $n = 908$ )	р	RSV+ ( $n = 129$ )	р	
Baseline characteristics						
Gender						
Women, <i>n</i> (%)	50/90 (56%)	430/908 (47%)	0.14	67/129 (52%)	0.60	
Men, <i>n</i> (%)	40/90 (44%)	478/908 (53%)		62/129 (48%)		
Age						
Median age, years (IQR)	78 (70-86)	69 (54-82)	< 0.001	74 (64-84)	0.06	
Age >65 years, $n(\%)$	76/90 (84%)	538/908 (59%)	< 0.001	95/129 (74%)	0.06	
Median BMI, kg/m <sup>2</sup> (IQR)	24.8 (21.5-28.5)	25.1 (22.1-28.4)	0.85	24.6 (21.6-28.8)	0.91	
Smoking status						
Smoker, $n$ (%)	12/87 (14%)	178/874 (21%)	0.12	31/126 (25%)	0.05	
Ex-smoker, $n(\%)$	28/87 (32%)	260/874 (30%)	0.72	44/126 (35%)	0.70	
Non-smoker, n (%)	47/87 (54%)	420/874 (49%)	0.37	51/126 (40%)	0.05	
Chronic diseases (at least one), $n$ (%)	73/90 (81%)	678/908 (75%)	0.18	117/129 (91%)	0.04	
Chronic respiratory disease, $n(\%)$	40/90 (44%)	344/908 (38%)	0.22	70/129 (54%)	0.15	
Chronic heart disease, $n$ (%)	45/90 (50%)	362/908 (40%)	0.06	64/129 (50%)	0.96	
Diabetes, n (%)	18/90 (20%)	204/908 (22%)	0.59	30/129 (23%)	0.57	
Chronic renal failure, $n$ (%)	9/90 (10%)	116/908 (13%)	0.45	26/129 (20%)	0.04	
Cancer, n (%)	13/90 (14%)	131/908 (14%)	0.99	33/129 (26%)	0.05	
Cirrhosis, $n(\%)$	4/90 (4%)	28/922 (3%)	0.52	4/129 (3%)	0.60	
Immunosuppressive treatment, $n$ (%)	15/90 (17%)	151/904 (17%)	0.99	26/128 (20%)	0.50	
Pregnancy, $n$ (% of women of childbearing age)	0	13/123 (11%)	1.00	0	1.00	
Influenza vaccination, n (%)	52/90 (58%)	351/919 (39%)	< 0.001	70/126 (56%)	0.68	
Hospitalization in the previous 12 months, $n$ (%)	37/90 (41%)	360/908 (40%)	0.79	64/129 (50%)	0.21	
Presence of child/children <5 years in the household, $n$ (%)	5/90 (6%)	69/915 (8%)	0.67	8/129 (6%)	0.84	
Clinical presentation				, , , ,		
Median time from symptom onset to hospitalization, days (IQR)	2(1-3)	2 (1-4)	0.23	2 (1-3)	0.7	
Symptoms						
Fever or feverishness, n (%)	79/90 (88%)	811/907 (89%)	0.63	109/128 (85%)	0.58	
Cough, <i>n</i> (%)	75/90 (83%)	784/908 (86%)	0.43	106/128 (83%)	0.92	
Dyspnea, n (%)	76/90 (84%)	650/908 (71%)	0.05	112/128 (88%)	0.42	
Weakness/malaise, $n$ (%)	13/90 (14%)	244/904 (27%)	0.01	29/128 (23%)	0.13	
Headache, n (%)	16/90 (18%)	277/902 (31%)	0.01	30/128 (23%)	0.31	
Myalgia, $n(\%)$	19/90 (21%)	260/897 (29%)	0.11	19/128 (15%)	0.23	
Sore throat, n (%)	8/90 (9%)	184/901 (20%)	0.008	22/126 (17%)	0.07	
Outcome						
At least one complication during the hospital stay, $n$ (%)	56/90 (62%)	473/908 (52%)	0.07	85/129 (66%)	0.58	
Pneumonia, n (%)	32/89 (36%)	257/904 (28%)	0.14	50/128 (39%)	0.64	
Respiratory failure, $n$ (%)	32/89 (36%)	254/904 (28%)	0.12	47/128 (37%)	0.91	
Acute heart failure, $n(\%)$	22/89 (25%)	114/903 (13%)	0.002	21/128 (16%)	0.13	
Acute respiratory distress syndrome, $n$ (%)	8/89 (9%)	83/904 (9%)	0.95	15/128 (12%)	0.52	
Median length of stay, days (IQR)	7 (4-13)	6 (3-10)	0.06	7 (5–14)	0.50	
ICU admission after hospitalization in acute care, $n$ (%)	15/90 (17%)	155/908 (17%)	0.88	33/128 (26%)	0.20	
Death, <i>n</i> (%)	4/90 (4%)	36/906 (4%)	0.78	9/129 (7%)	0.44	

BMI, body mass index; hMPV, human metapneumovirus; ICU, intensive care unit; IQR, interquartile range; RSV, respiratory syncytial virus.

control population (i.e. hospitalized adults without ILI symptoms) to help evaluate hMPV pathogenicity.

In conclusion, adult hMPV infections concerned 3% of patients hospitalized with ILI in tertiary care hospitals over six consecutive influenza seasons in France. Most of the patients were older, had associated chronic conditions and developed pulmonary and cardiac complications. The relation between hMPV infection and worsening of heart failure needs further investigation. These at-risk populations would benefit from the development of antivirals and vaccines targeting hMPV.

# **Transparency declaration**

The authors declare no competing interest related to the study. P.L. has received personal fees and non-financial support from Pfizer and Sanofi Pasteur. O.L. is an investigator for clinical trials sponsored by Janssen, GSK, Pfizer, Sanofi Pasteur and MSD and received travel support to attend scientific meetings from pharmaceutical companies. The current work received no funding. However, the study sites received funding from Sanofi Pasteur, Sanofi Pasteur MSD and Janssen for the FLUVAC study. Vaccine producers had no role in the study design, data analysis, decision to publish or preparation of the manuscript.

### **Authors' contributions**

P.L. and O.L. conceptualized the study. P.L. developed the methodology. P.M. did the analysis. P.L. and P.M. wrote the original manuscript. N.L., F.G., F.L., Z.L., P.V., X.D., D.P., S.A., S.R., G.L., A.S.L., V.F., N.H., B.L. and F.C. critically reviewed the manuscript. O.L. supervised the research.

# Acknowledgements

We thank Sarah Kabani for her editing assistance.

# Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2020.04.005.

### References

- leven M, Coenen S, Loens K, Lammens C, Coenjaerts F, Vanderstraeten A, et al. Aetiology of lower respiratory tract infection in adults in primary care: a prospective study in 11 European countries. Clin Microbiol Infect 2018;24:1158–63.
- [2] Souty C, Masse S, Valette M, Behillil S, Bonmarin I, Pino C, et al. Baseline characteristics and clinical symptoms related to respiratory viruses identified

among patients presenting with influenza-like illness in primary care. Clin Microbiol Infect 2019;25:1147–53.

- [3] Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, et al. Clinical practice guidelines by the infectious diseases society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin Infect Dis 2019;68:e1-47.
- [4] Stockton J, Stephenson I, Fleming D, Zambon M. Human metapneumovirus as a cause of community-acquired respiratory illness. Emerg Infect Dis 2002;8:5.
- [5] Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis 2003;187:785–90.
- [6] Panda S, Mohakud NK, Pena L, Kumar S. Human metapneumovirus: review of an important respiratory pathogen. Int J Infect Dis 2014;25:45–52.
- [7] Li Y, Reeves RM, Wang X, Bassat Q, Brooks WA, Cohen C, et al. Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet Glob Health 2019;7:e1031-45.
- [8] Principi N, Esposito S. Paediatric human metapneumovirus infection: epidemiology, prevention and therapy. J Clin Virol 2014;59:141–7.
- [9] Boivin G, Abed Y, Pelletier G, Ruel L, Moisan D, Côté S, et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 2002;186:1330–4.
- [10] Walsh EE, Peterson DR, Falsey AR. Human metapneumovirus infections in adults: another piece of the puzzle. Arch Intern Med 2008;168:2489.
- [11] Vidaur L, Totorika I, Montes M, Vicente D, Rello J, Cilla G. Human metapneumovirus as cause of severe community-acquired pneumonia in adults: insights from a ten-year molecular and epidemiological analysis. Ann Intensive Care 2019;24:86.
- [12] van den Hoogen BG. Respiratory tract infection due to human metapneumovirus among elderly patients. Clin Infect Dis 2007;44:1159–60.
- [13] European Centre for Disease Prevention and Control (ECDC). Influenza case definition. Available from: https://ecdc.europa.eu/en/surveillance-anddisease-data/eu-case-definitions.

- [14] Van den Hoogen BG, Osterhaus AD, Fouchier RA. Clinical impact and diagnosis of human metapneumovirus infection. Pediatr Infect Dis J 2004;23: S25–32.
- [15] Sentilhes A-C, Choumlivong K, Celhay O, Sisouk T, Phonekeo D, Vongphrachanh P, et al. Respiratory virus infections in hospitalized children and adults in Lao PDR. Influenza Other Respir. Viruses 2013;7: 1070–8.
- [16] Lim YK, Kweon OJ, Kim HR, Kim T-H, Lee M-K. Clinical features, epidemiology, and climatic impact of genotype-specific human metapneumovirus infections: longterm surveillance of hospitalized patients in South Korea. Clin Infect Dis 2019. Available from: https://academic-oup-com.proxy.insermbiblio.inist.fr/cid/ advance-article/doi/10.1093/cid/cic697/5540161.
- [17] Lefebvre A, Manoha C, Bour J-B, Abbas R, Fournel I, Tiv M, et al. Human metapneumovirus in patients hospitalized with acute respiratory infections: a meta-analysis. J Clin Virol 2016;81:68–77.
- [18] Haas LEM, de Rijk NX, Thijsen SFT. Human metapneumovirus infections on the ICU: a report of three cases. Ann Intensive Care 2012;2:30.
- [19] Hamelin ME, Cotu S, Laforge J, Lampron N, Bourbeau J, Weiss K, et al. Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease. Clin Infect Dis 2005;41:498–502.
- [20] Hasvold J, Sjoding M, Pohl K, Cooke CR, Hyzy RC. The role of human metapneumovirus in the critically ill adult patient. J Crit Care 2016;31:233–7.
- [21] Patel NJ, Nalluri N, Deshmukh A, Pant S, Shah N, Badheka AO, et al. Seasonal trends of heart failure hospitalizations in the United States: a national perspective from 2000 to 2011. Int J Cardiol 2014;173:562–3.
- [22] Ivey KS, Edwards KM, Talbot HK. Respiratory syncytial virus and associations with cardiovascular disease in adults. J Am Coll Cardiol 2018;71:1574–83.
- [23] Falsey A, Criddle M, Walsh E. Detection of respiratory syncytial virus and human metapneumovirus by reverse transcription polymerase chain reaction in adults with and without respiratory illness. J Clin Virol 2006;35: 46–50.